Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Bought by Financial Counselors Inc.

Financial Counselors Inc. lifted its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 80,197 shares of the medical research company’s stock after acquiring an additional 475 shares during the period. Financial Counselors Inc.’s holdings in Thermo Fisher Scientific were worth $41,721,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently bought and sold shares of TMO. Howard Capital Management Group LLC grew its stake in shares of Thermo Fisher Scientific by 0.5% during the 3rd quarter. Howard Capital Management Group LLC now owns 54,575 shares of the medical research company’s stock worth $33,759,000 after purchasing an additional 286 shares during the period. Principal Financial Group Inc. boosted its position in Thermo Fisher Scientific by 22.1% during the 3rd quarter. Principal Financial Group Inc. now owns 1,247,838 shares of the medical research company’s stock worth $771,876,000 after acquiring an additional 225,568 shares during the period. Landscape Capital Management L.L.C. acquired a new position in Thermo Fisher Scientific during the third quarter valued at $235,000. Dai ichi Life Insurance Company Ltd raised its holdings in shares of Thermo Fisher Scientific by 1.0% during the 3rd quarter. Dai ichi Life Insurance Company Ltd now owns 17,707 shares of the medical research company’s stock valued at $10,953,000 after purchasing an additional 168 shares in the last quarter. Finally, FMR LLC lifted its stake in shares of Thermo Fisher Scientific by 19.7% in the third quarter. FMR LLC now owns 7,877,459 shares of the medical research company’s stock valued at $4,872,761,000 after buying an additional 1,294,453 shares during the period. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have issued reports on the stock. StockNews.com raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Tuesday, January 14th. Wells Fargo & Company boosted their price target on Thermo Fisher Scientific from $660.00 to $680.00 and gave the stock an “overweight” rating in a research note on Friday, January 31st. Raymond James restated an “outperform” rating and set a $667.00 target price (up previously from $650.00) on shares of Thermo Fisher Scientific in a report on Monday, February 3rd. Scotiabank boosted their price objective on shares of Thermo Fisher Scientific from $605.00 to $650.00 and gave the company a “sector perform” rating in a report on Monday, February 3rd. Finally, Bank of America dropped their target price on shares of Thermo Fisher Scientific from $675.00 to $660.00 and set a “buy” rating for the company in a report on Friday, December 13th. Four investment analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $653.23.

Thermo Fisher Scientific Stock Performance

Shares of TMO opened at $513.77 on Wednesday. The business’s fifty day simple moving average is $544.56 and its two-hundred day simple moving average is $554.22. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59. The company has a market cap of $193.83 billion, a price-to-earnings ratio of 31.08, a P/E/G ratio of 2.99 and a beta of 0.79. Thermo Fisher Scientific Inc. has a 12 month low of $493.30 and a 12 month high of $627.88.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Thursday, January 30th. The medical research company reported $6.10 earnings per share for the quarter, topping the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. Research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, April 15th. Investors of record on Friday, March 14th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 0.33%. The ex-dividend date of this dividend is Friday, March 14th. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. Thermo Fisher Scientific’s dividend payout ratio is presently 10.41%.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total value of $175,677.00. Following the transaction, the executive vice president now owns 16,363 shares of the company’s stock, valued at $9,582,009.17. The trade was a 1.80 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Michael A. Boxer sold 3,775 shares of Thermo Fisher Scientific stock in a transaction on Monday, March 10th. The stock was sold at an average price of $532.52, for a total transaction of $2,010,263.00. Following the sale, the senior vice president now owns 10,816 shares of the company’s stock, valued at $5,759,736.32. The trade was a 25.87 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 23,900 shares of company stock worth $13,106,062 over the last quarter. Insiders own 0.34% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.